EN

Pipeline

Product /
Indication
Key Differentiation /
Platform
Preclinical
IND
Pilot-Scale
Clinical
Trials
Pivotal
Clinical
Trials
NDA
Partner
Triastek
Rights
Product/Indication: T19
RA, PsA, AS
Key Differentiation/Platform: Efficacy Improvement
3DμS®-DR
Phase: Pivotal Clinical Trials
US/China
NDA: 2025E
Triastek Rights: Global

    January 2021

    FDA IND Clearance

    July 2022

    NMPA IND Clearance

    China's first IND clearance for 3D printed drug

    Differentiation: Efficacy improvement through chronotherapy matching drug release with disease onset

    Platform: 3D Microstructure for Delayed Release

Product/Indication: T20
AF, VTE
Key Differentiation/Platform: Adherence Improvement
3DμS®-SE
Phase: Pilot-Scale Clinical Trials
US
NDA:
Triastek Rights: Global

    March 2022

    FDA IND Clearance

    Differentiation: Adherence improvement through reduce dosing frequency

    Platform: 3D Microstructure for Solubility Enhancement

Product/Indication: T21
UC
Key Differentiation/Platform: Safety Improvement
3DμS®-CT
Phase: Pilot-Scale Clinical Trials
US
NDA:
Triastek Rights: Global

    November 2022

    FDA IND Clearance

    Differentiation: Safety improvement through disease site specific delivery to reduce system exposure

    Platform: 3D Microstructure for Colon Targeting

Product/Indication: T22
PAH
Key Differentiation/Platform: Adherence Improvement
3DμS®-GR
Phase: IND
US/China
NDA:
Partner: 曙方医药
Triastek Rights: Ex-East Asia
Product/Indication: D23
IgAN
Key Differentiation/Platform: Process Optimization
3DμS®-MR
Phase: IND
US/China
NDA:
Triastek Rights: Global
Product/Indication: Not Disclosed
Key Differentiation/Platform: Adherence Improvement & Treatable Population Expansion
3DμS®-OP
Phase: Preclinical
NDA:
Triastek Rights: Global
    Product
    T19
    Indication
    RA, PsA, AS
    Key Differentiation
    Efficacy Improvement
    Platform
    3DμS®-DR
    Phase
    Pivotal Clinical Trials
    NDA
    2025E
    Triastek Rights
    Global

    January 2021

    FDA IND Clearance

    July 2022

    NMPA IND Clearance

    China's first IND clearance for 3D printed drug

    Differentiation: Efficacy improvement through chronotherapy matching drug release with disease onset

    Platform: 3D Microstructure for Delayed Release

    Product
    T20
    Indication
    AF, VTE
    Key Differentiation
    Adherence Improvement
    Platform
    3DμS®-SE
    Phase
    Pilot-Scale Clinical Trials
    Triastek Rights
    Global

    March 2022

    FDA IND Clearance

    Differentiation: Adherence improvement through reduce dosing frequency

    Platform: 3D Microstructure for Solubility Enhancement

    Product
    T21
    Indication
    UC
    Key Differentiation
    Safety Improvement
    Platform
    3DμS®-CT
    Phase
    Pilot-Scale Clinical Trials
    Triastek Rights
    Global

    November 2022

    FDA IND Clearance

    Differentiation: Safety improvement through disease site specific delivery to reduce system exposure

    Platform: 3D Microstructure for Colon Targeting

    Product
    T22
    Indication
    PAH
    Key Differentiation
    Adherence Improvement
    Platform
    3DμS®-GR
    Phase
    IND
    Partner
    Triastek Rights
    Ex-East Asia
    Product
    D23
    Indication
    IgAN
    Key Differentiation
    Process Optimization
    Platform
    3DμS®-MR
    Phase
    IND
    Triastek Rights
    Global
    Product
    Not Disclosed
    Indication
    Not Disclosed
    Key Differentiation
    Adherence Improvement & Treatable Population Expansion
    Platform
    3DμS®-OP
    Phase
    Preclinical
    Triastek Rights
    Global

RA: Rheumatoid Arthritis; PsA: Psoriatic Arthritis; AS: Ankylosing Spondylitis; AF: Atrial Fibrillation; VTE: Venous Thromboembolism; UC: Ulcerative Colitis; PAH: Pulmonary Arterial Hypertension

Business Development

Contact Us

苏ICP备17053162号 苏公网安备 32011502011777号

All Rights Reserved

Copyright © 2024 (TRIASTEK)

Contact Us

BD@triastek.com

Follow us on

Global

COPYRIGHT © 2024 TRIASTEK. 苏ICP备17053162号

DIGITAL By VTHINK